Navigation Links
The Financial Impact of Obesity in Brazil and Mexico's Healthcare Systems is Driving Partial Coverage of Obesity Drugs in Formularies at the State, Municipal and Hospital Levels

BURLINGTON, Mass., July 22, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while prescription weight-loss drugs currently lack nationwide coverage in Brazil and Mexico, the high and increasing prevalence of obesity and its associated healthcare costs are motivating openness to government coverage of certain brands. In Mexico, approximately half of surveyed physicians can access Roche's Xenical, or generic equivalents, through hospital and/or state formularies. In Brazil, recently issued government guidelines for the prevention and treatment of obesity provide a framework for incorporation of safe and effective weight-loss drugs into formularies at the state and municipal levels.


The Emerging Markets Physician & Payer Forum report entitled Obesity in Brazil and Mexico: Physician and Payer Perspectives on Prescribing Trends, Patient Access and Reimbursement Challenges Facing Current and Emerging Therapies finds that demand is high for weight-loss therapies that can demonstrate acceptable cost-benefit ratios to national and institutional health technology assessment (HTA) bodies. After COFEPRIS's withdrawal of Abbott's Reductil in Mexico, and ANVISA's withdrawal of amphetamine drugs in Brazil, up to 51 percent of surveyed physicians turn to off-label therapies, such as Nordisk's Victoza, Eli Lilly's Byetta and Janssen's Topamax, despite high out-of-pocket payments associated with these drugs.

"The shortcomings of existing drugs and the market withdrawal of amphetamine agents has spurred discussion among the government/payers, providers and industry on how to address the burgeoning costs of obesity on Latin American healthcare systems," said Decision Resources Analyst Andreia Ribeiro, Ph.D. "Payers seek more efficacious therapies and indicate that drugs with different mechanisms of action would be attractive to regulators seeking to expand the obesity treatment armamentarium. Some payers find high value in data from studies directly comparing obesity drugs, but all interviewed payers agree that studies demonstrating cost-effectiveness—a key parameter determined during HTA evaluations in Latin America—are critical to securing formulary inclusion of new drugs."

Several therapies may impact the obesity markets in Brazil and Mexico during the next few years, including Vivus' Qsymia, which appears to offer the best clinical efficacy among marketed or late-stage developmental drugs; Arena/Eisai's Belviq, which offers a more convenient delivery route and dosing schedule than thrice-daily Xenical or the injectable agents currently used off-label; and GLP-1 analogues, which will likely be first choice for (pre)diabetic obese patients. The report findings highlight key positioning attributes for weight-loss agents identified by physicians and payers that may drive Latin America formulary coverage decisions, including cardiovascular safety profile, impact on obesity-related comorbid disease and the downstream cost savings offered to these particular healthcare systems.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
7. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. Lexicon to Provide First Quarter 2012 Financial Results
10. Chindex International, Inc. to Report First Quarter 2012 Financial Results
11. Anthera Announces First Quarter 2012 Financial Report and Conference Call
Post Your Comments:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
Breaking Medicine News(10 mins):